Kamada is a biopharmaceutical company engaged in developing, producing, and marketing specialty life-saving therapeutics, using a unique protein purification technology. Kamada's product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA-approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use, and stabilizer-free augmentation treatment. Kamada has a strategic agreement with Baxter for US marketing, distribution, and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD, as well as type-1 diabetes for which the company started a clinical trial. In addition to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada's unique know-how and capabilities enable it to seek new business opportunities and offer a wide scope of pharma-oriented services, including R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration, and marketing. Over the years, Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture, and provide high quality, specialty pharmaceuticals to patients in order to support better quality of life and save lives.
Something looks off?